# Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

> **NCT06233357** · — · COMPLETED · sponsor: **University of Ulm** · enrollment: 95 (actual)

## Conditions studied

- COVID-19
- Outcome, Fatal
- Tocilizumab
- Interleukin 6
- Critically Ill

## Interventions

- **DRUG:** treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)

## Key facts

- **NCT ID:** NCT06233357
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-01
- **Primary completion:** 2022-04-28
- **Final completion:** 2023-12-31
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06233357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06233357, "Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06233357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*